Low

CI-VAR-00002550Explore in graph →CIViC 5212

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Mesothelioma1
TMB Low	Nivolumab	Predictive	B	Does Not Support Sensitivity Response	1	accepted	EID12918 This is part of a randomised phase 3 trial, CheckpOiNt Blockade For the Inihibition of Relapsed Mesothelioma (CONFIRM), that examined therapeutic response to the anti-PD1 inhibitor, nivolumab, in pati… (full text at CIViC) PMID 40691143 · Fennell et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.